Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $370,600 - $471,100
-10,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $402,600 - $573,700
10,000 New
10,000 $443,000
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $8.76 Million - $13.4 Million
-150,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$41.13 - $62.45 $6.17 Million - $9.37 Million
150,000 New
150,000 $9.17 Million
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $14.3 Million - $26.3 Million
-160,500 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $6.6 Million - $11.2 Million
80,500 Added 100.63%
160,500 $15.4 Million
Q1 2018

May 15, 2018

SELL
$152.15 - $192.33 $52.5 Million - $66.4 Million
-345,000 Reduced 81.18%
80,000 $12.9 Million
Q4 2017

Feb 14, 2018

BUY
$60.72 - $167.34 $14.9 Million - $41 Million
245,000 Added 136.11%
425,000 $70 Million
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $11.1 Million - $15.9 Million
180,000
180,000 $11.2 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.